

genflowbiosciences

longer better life

GENF.L

CORPORATE PRESENTATION

JUNE 2022

# DISCLAIMER

The sole purpose of this investor presentation, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the “Presentation”) is to provide information on Genflow Biosciences Plc and its subsidiary companies (“Genflow” or “the Company”) in relation to a proposed (i) placing of new ordinary shares (the “Placing Shares”) in the capital of the Company and (ii) admission of the Placing Shares and the whole of the issued and to be issued ordinary share capital of the Company to the Official List of the Financial Conduct Authority (“FCA”) by way of a standard listing under Chapter 14 of the Listing Rules published by the FCA under section 73A of the Financial Services and Markets Act 2000 (“FSMA”) (as amended from time to time) and to trading on the London Stock Exchange’s Main Market for listed securities (“Admission”) (together, the “Transaction”).

This Presentation is strictly private and confidential and is intended solely for the information of the recipient. It is not an invitation for public subscription and should not be reproduced or circulated or used for any purpose. This Presentation is made available to you strictly on the basis that the information contained within this Presentation constitutes confidential information, and accordingly this Presentation, and all confidential information provided, are returnable to Genflow. Notice is given that:

1. The information relating to the Company contained herein has been provided by the Directors and has not been approved by the FCA.
2. Clear Capital Markets Limited (“Clear Capital”) is acting as broker to the Company and no one else in connection with the proposals contained in this Presentation. Accordingly, recipients should note that Clear Capital is neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Clear Capital under the Conduct of Business Rules of the FCA nor for providing advice in relation to the proposals contained in this Presentation.
3. In no circumstances will the Directors, the Company, nor Clear Capital, or any of their respective, affiliates, representatives, partners, directors, officers, employees, advisers or agents (collectively “the Relevant Parties”) be responsible for any of the information in this Document, including any forecasts and details on the market. These are supplied as a guide only and do not purport to contain all the information that an interested party may require. By accepting this Presentation, the recipient acknowledges that it will be solely responsible for making its own investigations, including the costs and expenses incurred, and forming its own view as to the condition and prospects of the Company and the accuracy and completeness of the statements contained herein.
4. This Presentation includes certain statements, estimates and projections provided by the Company with respect to its anticipated future performance. Such statements, estimates and projections reflect various assumptions concerning anticipated results and are subject to significant business, economic and competitive uncertainties and contingencies, many of which are or may be beyond the control of the Company. Accordingly, there can be no assurance that such statements, estimates and projections will be realised. The actual results may vary from those projected, and those variations may be material. No representations are or will be made by any party as to the accuracy or completeness of such statements, estimates and projections or that any projection will be achieved.
5. None of the Relevant Parties has any authority to make or give any representation or warranty whatsoever in relation to the business or prospects of the Company and makes no such representation or warranty.
6. The information contained herein and any further information (whether written, electronic or oral) relating to the Company supplied by any of the Relevant Parties is, and will be, supplied on the condition that none of the Relevant Parties or any other person whatsoever is liable for any error, omission, or inaccuracy therein nor for any loss or damage sustained by an investor of the business placing reliance on such information, including any error or omission or inaccuracy resulting from any negligent act or omission of any of the Relevant Parties or any other person. No party accepts any responsibility or gives any undertaking to provide further information, including any information required to correct any earlier inaccuracy or error.

7. The information contained in the Presentation does not, and will not, form any part of a contract or offer for sale or to invest. Furthermore, it does not constitute an offer capable of acceptance and no binding commitment may be entered into on the basis of the information contained herein.
8. Any decision in connection with any proposed subscription for Placing Shares must be made solely on the basis of the information contained in the final form prospectus prepared in accordance with the United Kingdom Prospectus Regulation Rules and to be published by the Company in connection with the Transaction (“Prospectus”). The Prospectus will supersede all information provided to you before the date of the Prospectus, and your investment decision, if any, must be made only on the basis of the information contained therein.
9. None of the Relevant Parties undertake to accept any proposal and they reserve the right to accept or reject any proposal for any reason. They reserve the right to negotiate with one or more potential parties at any time and to enter into a definitive agreement for a transaction involving the Company without prior notice to the recipient of this Presentation or other potential investors. They also reserve the right to terminate, at any time, further participation in the investigation and proposed process by any party, to modify any of the rules or procedures set forth herein or any other procedures without prior notice or assigning any reason therefore or to terminate the process contemplated hereby. They reserve the right to take any action, whether in or out of the conduct of the Company’s businesses, or the process contemplated by this Presentation.
10. Neither the receipt of this Presentation nor any information (whether written, electronic or oral) made available in connection with the proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment advice by any of the Relevant Parties.
11. This Presentation is directed only at persons who are persons having professional experience in matters relating to investments or are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc”) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons together being referred to as “relevant persons”). This Presentation must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Each recipient of this Presentation (“Recipient”) represents and warrants that he or it is a relevant person and agrees to inform himself or itself about and observe all applicable legal requirements in the UK and/or in the jurisdiction(s) in which he or it is situated. Any Recipient who is not a relevant person should return this document to the Company and should not act upon it.
12. This Presentation should not be considered as a recommendation by any of the Relevant Parties to invest in the Company, and recipients interested in investing in the Company are recommended to seek their own independent financial, legal and other advice from persons authorised and specialising, as necessary, in investments of the kind in question. Recipients should be aware that any investment activity may expose them to a risk of losing the property invested.
13. This Presentation is being supplied to you for your own information and may not be distributed, published, reproduced or otherwise made available to any other person, in whole or in part, for any purposes whatsoever. In particular, they should not be distributed to or otherwise made available to persons with addresses in Canada, Australia, Japan, the Republic of South Africa or the United States, its territories or possessions or in any other jurisdiction outside of the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements.
14. Recipients of this Presentation in jurisdictions outside the UK should inform themselves about and observe all applicable legal requirements in their jurisdictions. In particular, the distribution of this Presentation in certain jurisdictions may be restricted by law and, accordingly, recipients represent that they are able to receive this Presentation without contravention of any unfulfilled registration requirements or other legal restrictions in the jurisdiction in which they reside or conduct business.



# EXECUTIVE SUMMARY

## DISRUPTIVE ANTI-AGEING DRUG

- Developing transformative gene therapies targeting the upstream biology of ageing
- GF-1002 ( the Company's lead candidate) extensive preclinical data suggests extension of life and health span



## DIVERSIFIED PLAN

- The company is undertaking pre-clinical trials following admission
- The company intends to develop its lead compound for the treatment of Werner Syndrome (WS) patients (an accelerated ageing disease)
- Risk is mitigated with an additional focus on the veterinary program



## EXPERIENCED TEAM

- Exceptional team with decades of experience in the pharmaceutical and health industries
- First rate academics from top universities and industry leaders





# SCIENTIFIC ADVISORY BOARD



**DR. ERIC VERDIN MD  
PHD**  
CEO & President of



**DR. VERA GORBUNOVA PHD**  
Co-Director of




**DR. MATTHEW HIRSHEY PHD**  
Assistant Professor at



**DR. MANLIO VINCIGUERRA PHD**  
Principal Investigator at



Affiliated with



Affiliated with



Affiliated with



Affiliated with





# ABOUT GENFLOW BIOSCIENCES

Genflow Biosciences Plc is a UK based biotech company with R&D facilities in Belgium and an office in Cambridge, MA, driven by one mission: **to deliver medicines that potentially halt, slow, or reverse the ageing process in humans and dogs.**

Genflow is listed on the London Stock Market (**GENF.L**)

Genflow's lead compound, GF-1002, works through a **centenarian variant** (a variant gene found in people living to 100 years or more) of the **SIRT6 gene** and has yielded promising preclinical results.

Managed by an experienced team with decades of experience in the pharmaceutical and biotech industries, the company is optimistic that development programs will continue **at pace in the next 24 months.**





# AGEING

Age related diseases are the biggest health burden we face

Genflow treats ageing as the underlying risk factor for these diseases

Given the key role of genes in determining how we age Genflow focuses on gene therapeutics



2 years  
life expectancy



10-13 years  
life expectancy



88 years\*  
life expectancy

\*expected LE in relation to baby boys born in the UK in 2018

Source: Morgan AE, Davies TJ, Mc Auley MT. The role of DNA methylation in ageing and cancer. Proc Nutr Soc. 2018 Nov;77(4):412-422. doi: 10.1017/S0029665118000150. Epub 2018 Apr 30. PMID: 29708096




# GENE REGULATION IN AGEING

Ageing is a function of overworked epigenetic regulator genes unable to respond to cellular DNA damage.

Many genes regulate ageing: we are focusing on the SIRT6 gene.

Sirtuin 6 Gene  
(SIRT6)



genflowbiosciences

Ageing is driven by 9 interlinked Hallmarks, all rooted in DNA damage. Targeting one individual factor is unlikely to be effective.



Sources:  
R. White. J. Vijg. Do DNA DSB drive Ageing? Molecular Cell 63, September 1, 2016  
Mao, Z et al SIRT6 promotes DNA repair under stress by activating PARP1. Science 332, 2011,1443-1446  
F. Wang, CH Chan, K. Chen, et al. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogenes 31, no. 12. March 2012: 1546-57





# SIRT6 – REPAIRING DNA

SIRT6 gene/protein repairs DNA damage (especially double strand breaks (DSB)) and prevents senescence of our cells

- SIRT6 gene codes for SIRT6 protein
- Stronger SIRT6: Longer lifespan
- DSB repair coevolves with maximum lifespan (MLS) in rodents
- The activity of SIRT6 in stimulating DSB repair coevolves with MLS in rodents
- 5 amino acids determine the differential activities of mouse and beaver SIRT6

SIRT6 Efficiency Double Strand Break Repair






Source: Tian et al., 2019, Cell 177, 622–638 April 18, 2019



# FOCUS ON CENTENARIAN SIRT6

SIRT6 centenarian variant gene has more efficient DNA repair properties





# ACTING UPSTREAM

As organisms become more sophisticated, the biology of ageing becomes more complex.

This makes it more difficult to solve the problem, and increases the importance of acting early in managing ageing.

SIRT6 has been shown to extend the lifespan of virtually every organism on which it has been tested.



Mouse

Lifespan x 1.35

Sources: P. Oberdoerffer, S. Michan, M. McVay, et al. DNA damage-induced alterations in chromatin contribute to genomic integrity and age-related changes in gene expression. Cell 135. no. 5. Nov. 2008. 907-18 M. De Cecco, S. W. Criscione et al. Genomes of replicatively senescent cells undergo global epigenetic changes leading to gene silencing and activation of transposable elements. Ageing Cell 12. no. 2 April 2013:247-56





# DELIVERY SYSTEM: SAFE AND COST-EFFECTIVE

The patent-pending technology has already been tested in several preclinical studies

01

Non-integrating, no  
risk of insertional  
oncogenesis

02

Non-replicating,  
safe transient  
expression


03

Reduced potential  
for  
immunogenicity



# ADVANTAGES OF EXOSOME BASED DELIVERY

**Exo-AAV can mediate efficient, specific, and more durable SIRT6 expression in liver compared to conventional AAV**



## Efficient loading of AAVs into the exosome lumen



# INTELLECTUAL PROPERTY




EFS ID	1-21069	43268050
Application Number	US 63/188,573	US 63/222,557
Title of Invention	Variants of SIRT6 for use in preventing and/or treating age-related diseases	Method of in vivo administration of the coding sequence of the SIRT6 gene via Adeno-Associated-Virus
First Named Inventor	Vera Gorbunova, Seluanov and Suh	Eric Leire
Receipt Date	May 14, 2021	July 16, 2021
Ownership	Worldwide Exclusive license from University Rochester New York / Columbia University / Albert Einstein College of medicine	Genflow Biosciences SRL

Applications are being made to the USPTO to patent Genflow’s proprietary technology.










# PRODUCT PIPELINE






# LONGEVITY LANDSCAPE

COMPANY	OVERVIEW	TECHNOLOGY	HALLMARK OF AGEING FOCUSED ON	LOCATION
	Clinical stage (osteoarthritis Phase 2) public (Nasdaq) biotech	Anti-senescence (small molecules senolytic)	Senescence	USA, San Francisco, CA
	Private biotech developing therapeutics to address a range of degenerative diseases, regenerative medicine and	Regenerative medicine Stem cell and small molecules	Stem cell exhaustion	USA, San Diego, CA
	Private biotech developing medicines to treat ageing and ageing-related diseases	Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor	Proteostatis	USA, Richmond, CA
	Public (Nasdaq) biotech	Small molecules to activate progenitor cells Hearing loss	Stem cell exhaustion	USA, Woburn, MA
	Private biotech targeting ageing	Epigenetic reprogramming; Autophagy; mitochondrial dysfunction	Mitochondrial dysfunction	USA, Boston, MA
	Private biotech developing drugs to fight age-related neurological diseases	Protein-based drugs	Proteostatis	USA, Boston, MA
	Private biotech developing gene therapy for dogs with mitral valve pathology.	Gene therapy	Proteostatis	USA, San Carlos, CA




# VETERINARY PROGRAM

Genflow is developing the same delivery system for dogs. This has several advantages.







genflow**biosciences**  
longer better life

Genflow Biosciences Plc 15  
Ingestre Place London, UK  
W1F 0DU

Genflow Biosciences SRL  
Biopark Gosselies  
48 rue Auguste Piccard 6041  
Gosselies, Belgium

Genflow Biosciences Inc  
Harvard Square  
18 Brattle Street, Suite 400  
Cambridge, MA 02138, US

[www.genflowbio.com](http://www.genflowbio.com)